The influence of proton pump inhibitor therapy on the clinical course of COVID-19

The influence of proton pump inhibitor therapy on the clinical course of COVID-19 - COVID.PPI

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00021523

Enrollment

152

Registered

2020-04-27

Start date

2020-04-30

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

SARS-CoV2 J12.8 J80.0

Interventions

Group 1: Patients who are hospitalized due to confirmed SARS-CoV2 infection since January 2020 will be included in this data analysis. Baseline and laboratory data as well as complications during the

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Confirmed SARS-CoV2- infection, hospitalized patients

Exclusion criteria

Exclusion criteria: SARS-CoV2 infection excluded, outpatient treatment

Design outcomes

Primary

Measure	Time frame
1. Prevalence of bacterial superinfection in patienst with and without proton pump inhibitor (PPI) treatment. 2. Development of ARDS in patients with and without PPI treatment.	—

Secondary

Measure	Time frame
1. Index mortality 2. Prevalence of intensive care treatment in patients with and without PPI treatment 3. Cours eof inflammatory markers in patients with and without PPI treatment and its impact on the development of disease associated complications	—

Countries

Germany

Contacts

Public ContactDominik Bettinger

Universitätsklinikum Freiburg Department Innere Medizin Klinik für Innere Medizin II

dominik.bettinger@uniklinik-freiburg.de0761/270-34010

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026